Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 356970
Upon exercise of the option, Licensor grants this exclusive license.
Licensee shall have the right to reference any Licensor DMFs applicable to the Licensed Product.
Patents relate to the development of abuse deterrent formulation of hydrocodone for the treatment or relief of pain using Altus' Intellitabâ„¢ drug delivery platform.
IPSCIO Record ID: 344574
— an exclusive, worldwide, license under Licensors rights in Patent Rights to develop, have developed, make, have made, use, have used, sell, have sold, offer for sale, import and have imported Products;
— a non-exclusive, worldwide, license under Licensors rights in Technological Information;
— the right to sublicense Patent Rights exclusively licensed to Licensor.
The patent is titled Methods of decreasing or preventing pain using spicamycin or derivatives thereof.
IPSCIO Record ID: 310525
For the Option for additional Territories of Canada and Mexico, Licensor grants an option to extend this Agreement to cover a sole and exclusive, license, on royalty terms that are substantially similar to those set forth in this Agreement, with the right to sublicense, to the Intellectual Property Rights including the right to develop, use, market, promote, and sell Product in Canada and Mexico.
For the Trademark License Grant, Licensor grants an exclusive right and license, to use the Trademark in connection with the marketing, promotion, advertising, and sale or other distribution of the Product in the Territory.
For the Submission Package, Licensor grants an option for a sole and exclusive license, with the right to sublicense, to the Intellectual Property Rights including the right to develop, use, market, promote, and sell a topical formulation of lidocaine in a gel formulation (Development Product), whether sold over-the-counter or by prescription, for human use which falls within the claims of the Licensed Patents.
If Licensee exercises its option, the parties agree to license such Intellectual Property Rights on terms to be mutually agreed to by the parties.based substantially on the terms of this Agreement.
The Patents are titled Method for Treating Nerve Injury Pain Associated with Shingles; Method for Treating Nerve Injury Pain Associated with Shingles Herpes-Zoster and Post-Herpetic Neuralgia) by Topical Application Of Lidocaine; Method for Treating Pain Associated with Herpes Zoster and Post-Herpetic Neuralgia; and, Method for Treating Nerve Injury Pain Associated with Shingles (Herpes-zoster and Post Herpetic Neuralgia) by Topical Application of Lidocaine.
Product means any topical formulation of lidocaine in a bandage and/or transdermal (Patch) formulation, whether sold over-the counter or by prescription, for human use which falls within the claims of the Licensed Patents.
Trademark shall mean the trademarks LIDODERM or TAKON that may be used to market the Product in the Territory.
Lidocaine patches are used to relieve the pain of post-herpetic neuralgia (PHN; the burning, stabbing pains, or aches that may last for months or years after a shingles infection). Lidocaine is in a class of medications called local anesthetics. It works by stopping nerves from sending pain signals.
Lidoderm(R) (Lidocaine Patch 5%) is a transdermal pharmaceutical patch product for the treatment of post-herpetic neuralgia.
Postherpetic neuralgia is the most common complication of shingles. The condition affects nerve fibers and skin, causing burning pain that lasts long after the rash and blisters of shingles disappear. The chickenpox (herpes zoster) virus causes shingles.
Licensee is a pharmaceutical company engaged in research, development, and marketing of various products, including pain management products.
IPSCIO Record ID: 368511
Subsequent Platform Technology. with respect to the Subsequent Product, shall mean and include that certain technology that is the subject matter of US Patent Application No. 60/783,181 for Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes, and any improvements thereto whether patentable or not.
Compound shall mean morphine sulfate and/or morphine polystyrene.
Initial Product shall mean the pharmaceutical formulation developed under this Agreement that is demonstrated to have Bioequivalence to KADIANÂ® Referenced Product
KADIANÂ® NT shall mean the abuse deterrent form of the KADIANÂ® Reference Product which is presently the subject of Phase Ill trials being performed by or on behalf of Licensee.
Subsequent Product shall mean the pharmaceutical formulation developed under this Agreement that is demonstrated to have Bioequivalence to KADIANÂ® Referenced Product, or as to which Licensee elects to proceed hereunder without Bioequivalence) containing the Compound as its single active ingredient in a Subsequent extended-release suspension formulation with a concentration of at least 30 mg/15 ml using Licensor Subsequent Platform Technology, at one specific strength that is developed as part of the Development and Regulatory Program. In the event that the Subsequent Product is not Bioequivalent to the KADIANÂ® Referenced Product, Licensee shall have the option, but not the obligation, to proceed with the Development and Regulatory Program as if the Subsequent Product achieved Bioequivalence.
Kadian (morphine sulfate) is a narcotic pain reliever used to treat moderate to severe pain.
Licensee will gain access to Licensor's LiquiXR(TM) technology, a novel and proprietary drug delivery platform for sustained release products in liquid form. The company plans to use this technology to develop an oral liquid product complementary to the company's KADIANÂ® solid dose product line.